Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | PTCy in unrelated and haploidentical donor alloHSCT in CML

Guillermo Ortí, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, outlines the rationale and design of a retrospective study exploring the outcomes of patients with chronic myeloid leukemia (CML) undergoing unrelated and haploidentical donor allogeneic hematopoietic stem cell transplantation (alloHSCT) with post-transplant cyclophosphamide (PTCy) prophylaxis compared to a historical cohort of patients who have received unrelated donor alloHSCT with calcineurin inhibitor prophylaxis. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.